Keros Therapeutics Announces Participation at Upcoming Healthcare Conferences
Rhea-AI Summary
Keros Therapeutics (Nasdaq: KROS), a clinical-stage biopharmaceutical company specializing in TGF-ß family protein signaling disorders, has announced its upcoming participation in two major healthcare conferences.
The company's Chair and CEO, Jasbir S. Seehra, Ph.D., will present at:
- The TD Cowen 45th Annual Healthcare Conference on March 3, 2025, at 9:50 a.m. ET
- The Leerink Partners Global Healthcare Conference on March 10, 2025, at 1:40 p.m. ET
Both presentations will be in a fireside chat format, with archived replays available on the Keros website's Investor section for 90 days post-event.
Positive
- None.
Negative
- None.
News Market Reaction – KROS
On the day this news was published, KROS gained 0.18%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
LEXINGTON, Mass., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today announced that Keros’ Chair and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate at the following healthcare conferences:
TD Cowen 45th Annual Healthcare Conference
- Date and Time: Monday, March 3, 2025 at 9:50 a.m. Eastern time
- Link: https://wsw.com/webcast/cowen177/kros/2049093
- Format: Fireside Chat Presentation
Leerink Partners Global Healthcare Conference
- Date and Time: Monday, March 10, 2025 at 1:40 p.m. Eastern time
- Link: https://wsw.com/webcast/leerink38/kros/2250987
- Format: Fireside Chat Presentation
For each presentation, an archived replay will be accessible in the Investors section of the Keros website at https://ir.kerostx.com for up to 90 days following the conclusion of each event.
About Keros Therapeutics, Inc.
Keros is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the TGF-ß family of proteins. Keros is a leader in understanding the role of the TGF-ß family of proteins, which are master regulators of the growth, repair and maintenance of a number of tissues, including blood, bone, skeletal muscle, adipose and heart tissue. By leveraging this understanding, Keros has discovered and is developing protein therapeutics that have the potential to provide meaningful and potentially disease-modifying benefit to patients. One of Keros’ product candidates, cibotercept (KER-012), is being developed for the treatment of pulmonary arterial hypertension and for the treatment of cardiovascular disorders. Keros’ second product candidate, KER-065, is being developed for the treatment of neuromuscular diseases. Keros’ most advanced product candidate, elritercept (KER-050), is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndrome and in patients with myelofibrosis.
Investor Contact:
Justin Frantz
jfrantz@kerostx.com
617-221-6042
FAQ
When is Keros Therapeutics (KROS) presenting at the TD Cowen Healthcare Conference in 2025?
What format will KROS presentations take at the 2025 healthcare conferences?
How long will KROS conference presentation replays be available to investors?
What therapeutic focus does Keros Therapeutics (KROS) specialize in?
When is Keros Therapeutics (KROS) scheduled to present at the Leerink Partners Conference?
